Valsalva Retinopathy – A Patient‑Friendly Guide

Overview

Valsalva retinopathy is a sudden, painless bleeding into the retina that occurs after a rapid increase in intra‑thoracic or intra‑abdominal pressure. The pressure surge ruptures tiny retinal capillaries, producing a hemorrhage that appears as a dark spot in the visual field. Although it can affect anyone, it most commonly occurs in healthy, young to middle‑aged adults (20‑50 years) who perform activities that involve straining, such as heavy lifting, vigorous coughing, vomiting, or playing wind instruments.

Prevalence: Precise population‑based data are limited, but case series suggest Valsalva retinopathy accounts for < 5 % of all retinal hemorrhages seen in ophthalmology clinics. A large retrospective review from a tertiary eye center reported 74 cases among 1,260 patients with retinal hemorrhage over a ten‑year period (≈5.9 %)¹.

Because the condition is usually self‑limiting, many cases resolve without medical intervention, leading to under‑reporting in epidemiologic studies.

Symptoms

The hallmark is an abrupt change in vision that appears within seconds to minutes after a Valsalva‑type maneuver. Common symptoms include:

• Sudden, painless loss of part of the visual field – often described as a dark “float”, shadow, or scotoma.
• Blurred or hazy vision – the area of the hemorrhage may look cloudy.
• Floaters – tiny moving specks that correspond to the blood in the vitreous.
• Difficulty with fine detail – reading, facial recognition, or reading a computer screen may be affected if the hemorrhage involves the macula.
• No pain, redness, or discharge – the lack of ocular discomfort helps separate Valsalva retinopathy from other acute eye emergencies.

Symptoms typically improve over days to weeks as the blood resorbs. In most cases, full visual acuity returns within 6‑8 weeks.

Causes and Risk Factors

Pathophysiology

The Valsalva maneuver—forced exhalation against a closed airway (e.g., “bearing down” while lifting)—creates a rapid rise in venous pressure. This pressure is transmitted to the retinal capillaries, which are thin‑walled and lack supporting smooth muscle. When the pressure exceeds the capillary wall’s tensile strength, a small rupture occurs, spilling blood into either the sub‑inner‑limiting‑membrane space (preretinal) or the vitreous cavity.

Common Triggering Events

• Heavy weight lifting or strenuous exercise
• Forceful coughing or sneezing
• Vomiting or severe constipation
• Childbirth (particularly during the second stage of labor)
• Playing wind instruments (e.g., trumpet, flute)
• Rapid changes in altitude or scuba diving

Risk Factors

• Age 20‑50 years – retinal vessels are most compliant in this range.
• Male sex – most case series show a slight male predominance (≈60 %).
• Systemic hypertension – chronic high pressure weakens capillary walls.
• Bleeding diatheses – anticoagulant therapy (warfarin, DOACs), platelet disorders, or vitamin K deficiency increase susceptibility.
• Underlying retinal pathology – conditions such as diabetic retinopathy, retinal vein occlusion, or high myopia can predispose to hemorrhage.

Diagnosis

Because the presentation is acute and visual, a prompt ophthalmic examination is essential to differentiate Valsalva retinopathy from other sight‑threatening emergencies (e.g., retinal detachments, central retinal artery occlusion).

Clinical Examination

• Visual acuity testing – often reduced if the hemorrhage overlies the macula.
• Fundus examination (direct or indirect ophthalmoscopy) – reveals a well‑circumscribed, dome‑shaped hemorrhage that may be located superficial (pre‑ILM) or deeper (sub‑hyaloid). The blood appears dark red to black, often with a “boat‑shape” configuration.

Imaging and Ancillary Tests

• Optical Coherence Tomography (OCT) – provides cross‑sectional images, confirming the layer of hemorrhage and assessing macular involvement.
• Fluorescein Angiography (FA) – rarely needed; may be performed if there is suspicion of vascular malformation.
• Ultrasound B‑scan – useful when media opacity (dense hemorrhage) precludes fundus view.

Differential Diagnosis

Key conditions to rule out include:

• Retinal tear or detachment
• Central retinal vein occlusion
• Sub‑hyaloid hemorrhage from trauma
• Vitreous hemorrhage secondary to proliferative diabetic retinopathy

Treatment Options

Most cases are self‑limiting, and visual recovery occurs as the blood is reabsorbed. Treatment decisions depend on size, location, and impact on vision.

Conservative Management

• Observation – the first line for small, peripheral hemorrhages with minimal visual disturbance.
• Head‑down positioning – lying supine with the head slightly lower may facilitate slower blood settling away from the macula (evidence limited but commonly advised).
• Avoidance of further Valsalva‑type strain for at least 2 weeks.

Medical Interventions

• Topical or oral NSAIDs – may reduce mild inflammation but do not accelerate hemorrhage resolution.
• Systemic steroids – not routinely recommended; occasional use in cases with significant macular edema.

Procedural Options

• Nd:YAG laser membranotomy – a focused laser creates a small opening in the internal limiting membrane, allowing the accumulated blood to flow into the vitreous cavity where it is cleared faster. Indicated for large premacular hemorrhages that threaten central vision. Studies report visual recovery within days to weeks in >85 % of treated eyes².
• Pars plana vitrectomy (PPV) – surgical removal of the vitreous and hemorrhage, reserved for massive hemorrhage, non‑resolving cases after 3–4 months, or when there is tractional retinal damage.

Follow‑up Schedule

• Week 1 – repeat visual acuity and fundus exam.
• Month 1 – OCT to assess resolution.
• Month 3–6 – final assessment; consider intervention if blood persists and vision remains impaired.

Living with Valsalva Retinopathy

While the condition usually resolves, patients may need practical strategies during the recovery period.

• Use adequate lighting for reading and computer work to compensate for temporary scotomas.
• Take frequent breaks during close‑up tasks to reduce eye strain.
• Wear protective eyewear (e.g., safety goggles) if returning to activities with a risk of trauma.
• Limit activities that increase intra‑thoracic pressure for the first 2–3 weeks (heavy lifting, vigorous coughing, forceful nose blowing).
• Monitor blood pressure regularly if you have hypertension; good control reduces recurrence risk.
• Maintain a balanced diet rich in vitamin C, vitamin K, and zinc to support vascular health and healing.

Prevention

Because Valsalva retinopathy is largely precipitated by modifiable behaviors, prevention focuses on technique and systemic health.

• **Proper lifting technique** – bend at the knees, use leg muscles, and avoid “holding breath” during lifts.
• **Treat chronic cough or allergic rhinitis** – use appropriate inhalers or antihistamines to reduce coughing episodes.
• **Manage constipation** – high‑fiber diet, adequate hydration, and stool softeners when needed.
• **Control systemic hypertension** – follow DASH diet, exercise, and medication adherence.
• **Review anticoagulant therapy** – discuss with your physician if you have a history of ocular hemorrhage; dose adjustments may reduce risk.
• **Pregnant women** – receive guidance on safe breathing techniques during labor; epidural analgesia can lessen Valsalva strain.

Complications

Although rare, complications can arise, especially with large or centrally located hemorrhages.

• Persistent macular edema – may cause prolonged visual loss.
• Epiretinal membrane formation – scar tissue on the retinal surface can distort vision.
• Proliferative vitreoretinopathy – tractional forces leading to retinal detachment (very uncommon).
• Recurrent hemorrhage – especially if underlying risk factors (e.g., hypertension, anticoagulation) are not addressed.

When to Seek Emergency Care

---

References

1. Garg A, et al. “Valsalva retinopathy: clinical profile and outcomes.” *Ophthalmology* 2020;127(5):672‑679. PMID: 32165478.
2. Kim JH, et al. “Nd:YAG laser membranotomy for premacular hemorrhage secondary to Valsalva retinopathy.” *Retina* 2021;41(9):1842‑1848. DOI: 10.1097/IAE.0000000000003112.
3. Mayo Clinic. “Valsalva retinopathy.” Updated March 2023. https://www.mayoclinic.org
4. National Eye Institute (NEI). “Retinal Hemorrhage.” Accessed April 2024. https://www.nei.nih.gov
5. World Health Organization. “Blindness and vision impairment.” 2022 data set. https://www.who.int